NYSE:EWMedical Equipment
Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients
Edwards Lifesciences (NYSE:EW) recently celebrated the FDA approval of its SAPIEN 3 TAVR therapy for asymptomatic aortic stenosis patients, a significant development in cardiac care. This milestone, coupled with robust Q1 earnings and updated financial guidance, likely bolstered investors' confidence, contributing to a 5% share price increase over the past month. The company’s advancements align with broader market trends, marked by a 2% rise, driven by strong earnings and positive economic...